期刊
INTERNAL MEDICINE
卷 59, 期 7, 页码 977-981出版社
JAPAN SOC INTERNAL MEDICINE
DOI: 10.2169/internalmedicine.3928-19
关键词
onconephrology; immune checkpoint inhibitors (CPI); pembrolizumab; immune-related adverse events (irAEs); IgA nephropathy; acute tubulointerstitial nephritis
Immune checkpoint inhibitors (CPIs), including pembrolizumab, are becoming common oncological treatments. CPIs have been associated with a significant risk of developing immune-related adverse events (irAEs), such as nephritis and interstitial nephritis. However, the occurrence of glomerulonephritis has only rarely been reported. We herein present the case of a 75-year-old woman with non-small cell lung carcinoma (NSCLC) who developed proteinuria and microscopic hematuria during treatment with pembrolizumab. Renal biopsy revealed tubulointerstitial nephritis and IgA nephropathy. Considering that a urinalysis showed no abnormality before treatment, the condition might have been induced by pembrolizumab. hi this report, we focus on the correct diagnosis and management of renal irAEs, which remain controversial.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据